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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: Studies on early surfactant administration during nasal continuous positive airway
pressure (NCPAP) [intubateesurfactanteextubate (INSURE)] have used continuous positive
airway pressure and INSURE in the first hours after birth, but in many centers patients are
transported from far away hospitals, reaching the center at a later time. The aim of this study
was to compare the effect of INSURE with only NCPAP in the management of respiratory
distress syndrome (RDS) in an outborn hospital.
Methods: This study was a controlled randomized clinical trial on 60 neonates who were trans-
ported to the neonatal intensive care unit of Boo-Ali Sina Hospital. Neonates born at 270/7 to
346/7 weeks of gestation, aged 12 hours, and diagnosed with RDS were placed on NCPAP and
then randomly assigned to INSURE or NCPAP alone. The primary outcome was the need for intu-
bation and mechanical ventilation on the basis of the criteria defined by us, and the secondary
outcomes were neonatal mortality and other complications of RDS.
Results: In 13 months, 60 eligible neonates were enrolled. Our participants in INSURE group
received surfactant at the mean age of 5.1 hours. The relative risk of need for mechanical
ventilation was 0.55 (95% confidence interval: 0.15e1.9, p Z 0.53), and the rate of mortality
or other complications of RDS was statistically similar between the two groups.eonatology, Boo-Ali Sina Hospital, Azadi Boulevard, Sari, Mazandaran, Iran.
om (M. Nakhshab).
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Comparison of INSURE with NCPAP alone in RDS treatment 89Conclusion: After the first few hours of life (mean age of 5.1 hours), the rate of mortality and
chronic lung disease and the need for mechanical ventilation were not statistically different
between patients receiving INSURE and those in receipt of NCPAP alone.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Most small premature neonates with respiratory distress
syndrome (RDS) require some methods of respiratory
support.1 In spite of newer modes introduced in me-
chanical ventilation, the rate of chronic lung disease
(CLD) has not reduced greatly,2 and mechanical ventila-
tion is still known as the major risk factor for the devel-
opment of CLD.2,3
Introduction of the continuous positive airway pressure
(CPAP) as a respiratory support in an early stage of RDS4,5
has been associated with lower rates of CLD.1,2,6,7 Hence,
it is considered as a popular mode of noninvasive venti-
lation.8,9 If used early, CPAP could decrease the subse-
quent need for intubation and mechanical venti
lation.2,3,6,10
Since the introduction of the combination of surfactant
and mechanical ventilation in the treatment of RDS in
1980,11 intratracheal surfactant administration has
remained as the main treatment of RDS.9 It has been shown
that surfactant therapy reduces mortality and complica-
tions of RDS. Earlier treatment with surfactant (within 2
hours of birth) is much more effective than later treatment
in decreasing mortality rate and complications of RDS.12,13
Administration of surfactant after a transient intubation
in spontaneously breathing infants was reported in 1990 in
Kuwait.14 Surfactant administration during nasal CPAP
(NCPAP) by transient intubation and rapid extubation (the
INSURE method: intubationesurfactanteextubation) was
shown to be effective in reducing the need for mechanical
ventilation.2,6,8,15
However, the INSURE method is not always successful, it
may be a more invasive method than CPAP alone, and its
failure could lead to worsening of the patient’s general
condition1,16e18 and unnecessary high expenses.1,12,19
The majority of trials comparing the effects of INSURE
with early NCPAP have been conducted in well-equipped
neonatal intensive care units (NICUs) in developed coun-
tries, and in most of them the treatment (NCPAP or sur-
factant) has begun very early. On the other hand, in many
areas of the world, facilities for CPAP therapy or adminis-
tration of surfactant are not available in all hospitals, and
so the patient requires to be transported to an equipped
NICU, which may lead to a delay of several hours in
treatment.
The purpose of this randomized, controlled study was to
compare the effect of INSURE with that of NCPAP alone in
reducing the subsequent need for mechanical ventilation
and complications of RDS in preterm infants with RDS in an
outborn NICU where patients arrive after a delay of several
hours.2. Materials and methods
From April 2011 to May 2012, we conducted a randomized,
controlled trial in the NICU of Boo-Ali Sina Hospital, which is
a level III university-affiliated NICU in Sari, Iran.
The study was approved by the Mazandaran University of
Medical Sciences Ethics Committee, established by Mazan-
daran University of Medical Sciences Research Council, and
registered with the Iranian Registry of Clinical Trials (IRCT).
The IRCT code was IRCT ID: IRCT 201205213512N2.
Inclusion criteria were as follows: gestational age of
270/7 to 34
6/7 weeks (estimated from the mother’s 1
st
trimester sonographic report, and if it was not available,
the gestational age was estimated based on the Ballard
score),20 diagnosis of RDS with the presence of respiratory
distress, tachypnea, supplemental oxygen requirement
[fraction of inspired oxygen (FiO2)  0.4 to maintain O2
saturation in the range of 88e95%], beginning of symptoms
in the first 6 hours of life, radiologic evidence of RDS in
chest X-ray, and an RDS score of more than 5.21 We enrolled
only the infants who were born in Imam Khomeini Hospital,
a university-affiliated institution, where NICU and facilities
of CPAP or surfactant administration were unavailable.
Therefore, any high-risk neonates were transported to Boo-
Ali Sina Hospital, about 5 km away.
Exclusion criteria were as follows: an Apgar score of <5
at 5 minutes, presence of major congenital anomalies, signs
and symptoms of chorioamnionitis in the mother (according
to the mother’s hospital records), premature rupture of
membranes (>12 hours), and need for intubation and me-
chanical ventilation (according to a defined criterion that is
discussed later) prior to randomization.
Written parental consent was obtained prior to transport
of the patient to Boo-Ali Sina Hospital. A random-number
table was used to assign each eligible neonate to one of the
two study groups: (1) early NCPAP alone and (2) early
NCPAP plus intubation, surfactant administration, and
extubation (INSURE) in a 1:1 ratio. These assignments were
enclosed in sealed, consecutively numbered, and opaque
envelopes that were opened at Boo-Ali Sina Hospital after
eligibility was determined.
All premature infants received the initial steps of
resuscitation22 and were made “stable”23 to make them
ready for transport. If the infant needed any positive
pressure ventilation (PPV), a T-piece resuscitator (Neopuff
infant resuscitator; Fisher & Paykel Healthcare, Inc.,
Auckland, New Zealand) with peak inspiratory pressure
(PIP) set at 20 cmH2O and positive end expiratory pressure
(PEEP) at 5 cmH2O was used.
At the time of admission to the NICU of Boo-Ali Sina
Hospital, the eligible infants were placed on NCPAP (Sindi,
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Puchheim, Germany) of 5 cmH2O and the FiO2 was adjusted
to 0.5 with binasal prongs; the randomization envelope was
opened and the allocated treatment (INSURE for the
treatment group and NCPAP alone for the control group)
was started.
Intravenous phenobarbital 10e15 mg/kg was adminis-
tered, prior to intubation, to infants randomly assigned to
the INSURE group. The correct position of the endotracheal
tube was determined by the evaluation of breath sounds,
chest rising, and the tip-to-lip length of the tube. Each dose
of Survanta (Abbott Laboratories, Abbott Park, IL, USA),
4 mL/kg, was divided into four equal aliquots and admin-
istered intratracheally (according to the manufacturer’s
instructions). After surfactant administration, the infants
were manually ventilated between aliquots for a brief
period of time (15e30 minutes) using Neopuff with the
previously mentioned settings. Then, if stable, they were
extubated to NCPAP with a pressure of 5 cmH2O.
Infants assigned to the control group remained on NCPAP
of 5 cmH2O, and the FiO2 was adjusted in such a way that
the SpO2 remained between 88% and 95%. If the SpO2 fell
below 88%, the CPAP would rise to 6 cmH2O.
Naloxan was not given to either group. Aminophyllin was
administered in loading (5 mg/kg) and maintenance doses
(1 mg/kg/8 hours) to all the participating patients as soon as
NCPAP was started and continued until the discontinuation of
NCPAP.
In both groups, if the infant was stable on NCPAP, had an
acceptable arterial blood gas (ABG) (pH > 7.20, PCO2 < 60,
PaO2> 50with FiO2<0.3), and had no respiratory distress for
48 hours, it was regarded as treatment success and NCPAP
was discontinued.
Treatment failure in the treatment group was deter-
mined when the infant could not be extubated within 1
hour of INSURE, and in both groups when there was a need
for mechanical ventilation within 5 days. Indications for
mechanical ventilation were as follows: (1) the presence of
prolonged (>20 seconds) or recurrent apnea accompanied
by bradycardia or desaturation below 85%; (2) pH < 7.20,
PCO2 > 60, and PaO2 < 50 on arterial blood gas, with a
maximum FiO2 of 0.7 and CPAP of 5e6 cmH2O; and (3)
progressive respiratory distress.
In case of treatment failure, in both groups, the infant
was intubated for mechanical ventilation. Then in the
control group, if an FiO2 of more than 0.3 was necessary to
maintain the SpO2 above 88%, the rescue dose of Survanta
was administered. In the INSURE group, if the FiO2
requirement remained above 0.3 after 6 hours of INSURE
procedure, the rescue dose of surfactant was given.
In both groups, if FiO2 was >0.3 after the first dose of
rescue surfactant, subsequent doses of surfactant were
administered every 6 hours up to a maximum of four doses.
Surfactant was not administered after 48 hours of age.
The method of surfactant administration was in accordance
with the manufacturer’s instructions (as mentioned for the
INSURE group).
This study was not blinded. The primary outcome was
the need for mechanical ventilation (treatment failure) as
described above.
The secondary outcomes were death, incidence of
CLD (defined as need for oxygen treatment at thepostconceptional age of 36 weeks as well as at 28 days of
age), pneumothorax, Grade III and IV intraventricular
hemorrhage,24 periventricular leukomalacia,25 retinopathy
of prematurity, duration of mechanical ventilation and
CPAP, duration of hospitalization, duration of the need for
O2, and doses of rescue surfactant administered.
All patients were followed for primary and secondary
outcomes until they were discharged or they died.
On the basis of a previous study, in which early surfac-
tant administration has been successful in reducing the
need for mechanical ventilation by 42% (43% in early sur-
factant group vs. 85% in controls),6 we estimated that with
an a value of 0.05 and a b value of 90%, a sample size of 28
infants per group was necessary. We decided to include a
final sample of 60 infants, 30 in each group.
The data were analyzed by SPSS13. Comparison of the
characteristics of infants at the time of randomization and
also effect of intervention on the primary and secondary
outcomes were analyzed using Student t test for continuous
data, and Fisher’s exact test or c2 test (as appropriate) for
categorical data.3. Results
During the study period, 145 infants were transported from
Imam Khomeini to Boo-Ali Sina Hospital. Sixty neonates
with gestational ages of more than 27e346/7 weeks were
eligible for the study. They were randomly assigned to two
groups: 30 in the treatment group and 30 in the control
group. All parents gave informed consent. All the patients
were followed up until discharge or death (Figure 1).
In this study, the mean gestational age of patients was
31.2  2.3 weeks. Baseline characteristics of the patients in
both groups were similar (Table 1), except for birth weight,
which was lower in the INSURE group (p < 0.05).
The mean age of beginning CPAP was 3.99  2 (1.5e12)
hours, 4.7  2.3 hours in the control group and 3.2  1.1
hours in the INSURE group (p Z 0.002). The RDS score was
not significantly different between groups.
In the treatment group, surfactant was administered at
the mean age of 5.1  1.4 hours after birth. Tables 2 and 3
show the results of primary and secondary outcomes. In the
INSURE group, all patients were extubated successfully.
The need for mechanical ventilation was not significantly
different between the two groups (16.7% vs. 26.7%,
p Z 0.53). There was no significant difference in mortality
rate between the two groups. The incidence of CLD, Grades
III and IV intraventricular hemorrhage, and periventricular
leukomalacia was not different between the two groups.
Pneumothorax was less frequent in the INSURE group
compared with the control group (0 vs. 6.7%), but it was not
statistically significant (p Z 0.49).
None of the patients in the INSURE group received
rescue surfactant after reintubation. Seven patients in the
control group received rescue surfactant (each of them
receiving only 1 dose of surfactant; 23.3%), which was
statistically significant (p Z 0.01).
There was no difference between groups with respect to
the duration of hospitalization and days on mechanical venti-
lation or CPAP, but the duration of the need for O2 was signif-
icantly lower in the INSURE group (5.9% vs. 7.8%, pZ 0.03).
145 infants were transported to Boo-
Ali Sina Hospital
85 did not meet inclusion 
criteria 
60 were 
eligible  
   60 underwent randomization 
 30 were assigned to receive   
NCPAP alone 
30 were assigned to receive 
INSURE method       
All were followed 
until discharge or death
 
All were followed 
until discharge or death 
8 had treatment 
failure 
5 had treatment failure 
3 had BPD 
1 died 1 died 
Figure 1 Flow diagram of study participants. BPDZ bronchopulmonary dysplasia; INSUREZ intubation, surfactant, extubation;
NCPAP Z nasal continuous positive airway pressure.
Table 1 Baseline characteristics of the participating
infants.
Characteristics Control
group
(N Z 30)
Treatment
group
(N Z 30)
p
Birth weight,
mean  SD, g
1709  241.9 1515  433.6 0.03
Gestational age,
mean  SD, wk
31.0  2.1 31.4  1.9 0.20
Male, n (%) 14 (46.7) 13 (43.3) > 0.99
C-section, n (%) 29 (96.7) 27 (90) 0.60
5-min Apgar score,
median
8 8 > 0.99
Prenatal steroids,
n (%)
26 (90) 28 (96) 0.60
RDS score,
mean  SD
6.2  0.9 6.5  1.0 0.14
Control group: NCPAP only; treatment group: INSURE method.
INSURE Z intubation, surfactant, extubation; NCPAP Z nasal
continuous positive airway pressure; RDSZ respiratory distress
syndrome; SD Z standard deviation.
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This study shows that among the 27e34-week-gestational-
age preterm infants with RDS, application of the INSURE
method, in comparison with NCPAP alone, bears no signifi-
cant advantage for reducing the rate of death, CLD, or the
need for intubation and mechanical ventilation, when it is
applied after the first few hours of life (in our study, after a
mean period of 5.1 hours).
CPAP is recognized as an effective and noninvasive
method in the treatment of RDS.26 The use of early CPAP
will prevent the progression of RDS, and it will decrease the
need of excess surfactant.8
In one study by Levesque et al in 2011,27 five strategies
were introduced as superior practices for the treatment of
respiratory problems in neonates to reduce the need for
mechanical ventilation, the use of surfactant, and costs.
This study emphasized the application of CPAP in three of
these five strategies, without the use of surfactant, for
better outcome of neonates.
However, in some premature neonates with RDS on
NCPAP, the need for intubation and surfactant
Table 2 Primary and major secondary outcomes.
Outcome Control
group
(N Z 30)
n (%)
Treatment
group
(N Z 30)
n (%)
RR (95% CI) p
Treatment
failure
(MV)
8 (26.7) 5 (16.7) 0.55 (0.15e1.9) 0.53
Death 1 (3.3) 1 (3.3) 1 (0.6e16.7) > 0.99
CLD 3 (10) 3 (10) 1 (0.18e5.4) > 0.99
Pneumothorax 2 (6.7) 0 (0) 0.49
IVH, Grade
III or IV
1 (3.3) 3 (10) 3.2 (0.31e32.8) 0.60
PVL 1 (3.3) 1 (3.3) 1 (0.6e16.7) > 0.99
ROP 3 (10) 2 (6.1) 0.6 (0.1e4.1) > 0.99
Control group: NCPAP only; treatment group: INSURE method.
CI Z confidence interval; CLD Z chronic lung disease;
INSURE Z intubation, surfactant, extubation;
IVH Z intraventricular hemorrhage; MV Z mechanical ventila-
tion; NCPAP Z nasal continuous positive airway pressure;
PVLZ periventricular leukomalacia; RDSZ respiratory distress
syndrome; ROP Z retinopathy of prematurity; RR Z relative
risk; SD Z standard deviation.
Table 3 Other secondary outcomes.
Outcome Control
group
(N Z 30)
Treatment
group
(N Z 30)
p
Rescue surfactant, n (%) 7* (23.3) 0 (0) 0.01
Length of hospitalization,
mean  SD, d
15.1  5.5 14.2  6.3 0.57
Days of MV, mean  SD 1.9  3.7 1.4  2.7 0.50
Days on oxygen, mean  SD 7.8  3.4 5.9  3.0 0.03
Days on NCPAP, mean  SD 4.4  2.3 3.2  1.1 0.35
Control group: NCPAP only; treatment group: INSURE method.
INSUREZ intubation, surfactant, extubation; MVZmechanical
ventilation; NCPAP Z nasal continuous positive airway pres-
sure; SD Z standard deviation.
* Each of them received only one dose of surfactant.
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early surfactant has already passed. The INSURE
method3,6,8 has the advantage of early administration of
surfactant in infants on NCPAP; however, the dangers of
intubation as well as the burden of cost are important
considerations in making decisions about surfactant
administration.1,17e19
When comparing our results with other randomized trials
on this subject, in agreement with our study, some studies
have also reported that the rates of CLD and mortality were
not different when comparing NCPAP to intubation and
surfactant administration. In a recent large study on the
comparison between three groups of prophylactic surfac-
tant, INSURE, and CPAP alone, no difference was found in
the rate of death or CLD between groups.1 A SUPPORT study
on infants with 24e27 weeks of gestation showed that the
rate of mortality or CLD did not differ between the CPAP
and early surfactant groups.10 In the study of the ColombianNeonatal Research Network on the comparison of NCPAP
with INSURE in infants with a gestational age of 27e31
weeks,2 in their lower gestational age stratum (27e29
weeks), the rate of CLD or mechanical ventilation was not
different between the two groups. Escobedo et al28 showed
that routine elective surfactant administration is not rec-
ommended for mild-to-moderate RDS.
Results of other studies have shown that INSURE is su-
perior to NCPAP in reducing the need for intubation and
mechanical ventilation,2,3,6,15 but there has been no sig-
nificant difference in the rate of CLD. In one study, Rojas
et al2 showed that very early administration of surfactant in
premature infants with RDS who were on NCPAP decreased
the need for mechanical ventilation, the incidence of
pneumothorax, and also the need for subsequent rescue
surfactant doses. In this study, the INSURE method was
performed in the 1st hour of life, but in our study it was
delayed (by a mean time of 5.1 hours), which may explain
the differences between the beneficial effects of INSURE.
However, similar to our results, the rates of mortality and
CLD were not different between groups.2 In addition, the
superior effect of INSURE in comparison with NCPAP alone
in decreasing the need for mechanical ventilation and
improving oxygenation has been demonstrated in various
studies.3,6,15 In these studies, too, the mortality and CLD
rates were not significantly affected by the INSURE method,
similar to our results. In these studies, the rate of antenatal
steroid administration was much less than that in our study,
which might explain why neonates on NCPAP alone had
better outcomes in our study. Although in the majority of
studies the rate of the need for mechanical ventilation was
reduced more by INSURE, a significant portion of patients
on NCPAP did well without surfactant. Similar to our study,
in many studies patients in the CPAP group needed more
rescue surfactant. In our study, however, 77% of infants of
the control group managed without surfactant treatment.
In Dunn et al’s1 study, 48% of patients on NCPAP did not
need any intubation, and 54% managed without the
administration of surfactant. In the study of Escobedo
et al28 only 29 of 67 infants in the control group needed
intubation. In addition, in the study of Rojas et al,2 only 26%
of infants in the NCPAP group needed surfactant adminis-
tration. Therefore, it seems that more than half of the
patients on NCPAP will not require intubation and surfac-
tant treatment. The increasing tendency to use antenatal
steroids can also lead to a reduced need for surfactant
administration in mild and moderate RDS.1,16
Our study showed that the duration of oxygen therapy
was lower with INSURE, which was also the conclusion of
other articles.3,6,15
Another concern is the availability of treatment facil-
ities. The majority of all deaths in children <5 years of age
occur in developing countries, one-third of which are
neonatal deaths.29 In many centers of the developing
world, the facility of CPAP application or surfactant
administration early after birth is not available, and the
neonates have to be transported to a higher-level center. In
the majority of cases, the transport process is long and
imposes delays, so NCPAP and INSURE procedures are star-
ted late. Consequently, surfactant administration is
delayed, rendering it less effective.13,30 In addition, the
high cost of administration of surfactant is an important
Comparison of INSURE with NCPAP alone in RDS treatment 93issue in under-resourced areas, which should be taken into
consideration.16
This study was not blinded. This could be a limitation of
this study, which could have influenced the decisions of
initiating mechanical ventilation and discontinuing CPAP or
oxygen despite the use of our defined criteria for the
initiation of mechanical ventilation and discontinuation of
CPAP. Another limitation is that birth weight was not
matched between the two groups. The relatively small
sample size of our study might be responsible, to some
extent, for exhibiting smaller differences between these
two therapeutic strategies; hence, larger clinical trials are
needed to demonstrate all the differences and clarify the
characteristics of the patients for whom INSURE would have
more beneficial effects.5. Conclusions
Although the INSURE method is effective for RDS in some
infants, the decision to use surfactant routinely for every
infant with RDS symptoms who is doing well on NCPAP
seems to be unjustified, especially in developing countries
and when the infant is delayed in reaching the NICU.
More studies are needed to determine which patients
would benefit the most from the INSURE method, to avoid
exposing patients to unnecessary intubation and excess
surfactant administration.Conflicts of interest
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